Literature DB >> 15358629

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.

Upendra Hegde1, Armando Filie, Richard F Little, John E Janik, Nicole Grant, Seth M Steinberg, Kieron Dunleavy, Elaine S Jaffe, Andrea Abati, Maryalice Stetler-Stevenson, Wyndham H Wilson.   

Abstract

We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease, and clinical surrogates of CNS spread. Multicolor flow cytometry using multiple antibody panels for light chains and B- and T-cell antigens identified neoplastic clones that constituted as little as 0.2% of total CSF lymphocytes. Among 51 newly diagnosed patients, 11 (22%) had occult CSF involvement. All 11 were detected by flow cytometry but only 1 by cytology (P = .002). Among 9 treated patients, CSF involvement was detected by flow cytometry alone in 2 and also by cytology in 1 case. CSF chemistry and cell counts were similar in patients with and without CSF lymphoma. Only the number of extranodal sites was associated with occult CSF lymphoma in newly diagnosed patients by univariate (P = .006) or logistic regression analysis (P = .012). We hypothesize that the biologic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related to the microenvironment. Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry.

Entities:  

Mesh:

Year:  2004        PMID: 15358629     DOI: 10.1182/blood-2004-05-1982

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

1.  My treatment approach to patients with diffuse large B-cell lymphoma.

Authors:  James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid.

Authors:  Prashant Tembhare; Constance M Yuan; John C Morris; John E Janik; Armando C Filie; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2012-02       Impact factor: 2.493

3.  Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Authors:  Kieron Dunleavy; Michelle A Fanale; Jeremy S Abramson; Ariela Noy; Paolo Fabrizio Caimi; Stefania Pittaluga; Samir Parekh; Ann Lacasce; John W Hayslip; Deepa Jagadeesh; Sunil Nagpal; Mary Jo Lechowicz; Rakesh Gaur; Andrea Lucas; Christopher Melani; Mark Roschewski; Seth M Steinberg; Elaine S Jaffe; Brad Kahl; Jonathan W Friedberg; Richard F Little; Nancy L Bartlett; Wyndham H Wilson
Journal:  Lancet Haematol       Date:  2018-12       Impact factor: 18.959

4.  Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.

Authors:  Giovanni Antonini; Maria Cristina Cox; Enrico Montefusco; Antonella Ferrari; Esmeralda Conte; Stefania Morino; Pamela Latino; Guido Trasimeni; Bruno Monarca
Journal:  J Neurooncol       Date:  2006-08-26       Impact factor: 4.130

5.  Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).

Authors:  Magdalena Adde; Gunilla Enblad; Hans Hagberg; Christer Sundström; Anna Laurell
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

Authors:  Steven H Bernstein; Joseph M Unger; Michael Leblanc; Jonathan Friedberg; Thomas P Miller; Richard I Fisher
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

8.  Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Authors:  Elisa J Pulczynski; Outi Kuittinen; Martin Erlanson; Hans Hagberg; Alexander Fosså; Mikael Eriksson; Marie Nordstrøm; Bjørn Østenstad; Øystein Fluge; Sirpa Leppä; Bente Fiirgaard; Hanne Bersvendsen; Unn-Merete Fagerli
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

9.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Authors:  Ticiana Leal; Julie E Chang; Minesh Mehta; H Ian Robins
Journal:  Curr Cancer Ther Rev       Date:  2011-11

10.  Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma.

Authors:  Marc C Chamberlain; James Fink
Journal:  J Neurooncol       Date:  2009-05-16       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.